Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 2;16(4):919-930.
doi: 10.1080/21645515.2019.1678998. Epub 2019 Nov 11.

Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis

Beatriz Coutinho De Oliveira  1   2 , Malcolm S Duthie  3 , Valéria Rêgo Alves Pereira  2
Affiliations
Review

Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis

Beatriz Coutinho De Oliveira et al. Hum Vaccin Immunother. .

Abstract

The leishmaniases are a collection of vector-borne parasitic diseases caused by a number of different Leishmania species that are distributed worldwide. Clinical and laboratory research have together revealed several important immune components that control Leishmania infection and indicate the potential of immunization to prevent leishmaniasis. In this review we introduce previous and ongoing experimental research efforts to develop vaccines against Leishmania species. First, second and third generation vaccine strategies that have been proposed to counter cutaneous and visceral leishmaniasis (CL and VL, respectively) are summarized. One of the major bottlenecks in development is the transition from results in animal model studies to humans, and we highlight that although American tegumentary leishmaniasis (ATL; New World CL) can progress to destructive and disfiguring mucosal lesions, most research has been conducted using mouse models and Old World Leishmania species. We conclude that assessment of vaccine candidates in ATL settings therefore appears merited.

Keywords: American Tegumentary Leishmaniasis; Leishmania spp; Leishmaniasis; immune response; vaccines.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Maturation and expansion of Leishmania vaccine development.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO . Leishmaniasis Fact Sheet. World Health Organization; [cited 2019. April 1]. Published 2017. Available from: https://www.who.int/en/news-room/fact-sheets/detail/leishmaniasis
    1. Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME.. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016;34(26):2992–95. doi:10.1016/j.vaccine.2015.12.071. - DOI - PubMed
    1. de Vries HJC, Reedijk SH, Schallig HDFH. Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol. 2015;16(2):99–109. doi:10.1007/s40257-015-0114-z. - DOI - PMC - PubMed
    1. Pearson RD, Sousa ADQ. Clinical spectrum of leishmaniasis. Clin Infect Dis. 2010;22(1):1–13. doi: 10.1093/clinids/22.1.1. - DOI - PubMed
    1. Mayrink W, De Carvalho Botelho AC, Magalhães PA, Batista SM, Lima ADO, Genaro O, Costa CAD, Melo MND, Michalick MSM, Williams P, et al. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop. 2006;39(1):14–21. doi:10.1590/S0037-86822006000100003. - DOI - PubMed

Publication types